Literature DB >> 15327888

Prostate cancer and the met hepatocyte growth factor receptor.

Beatrice S Knudsen1, Magnus Edlund.   

Abstract

The hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the Met protein tyrosine kinase, form a classic ligand-receptor system for epithelial-mesenchymal communications in the normal and cancerous prostate. This review illustrates the expression and activities of HGF/SF and Met during prostate development, homeostasis, and carcinogenesis. The participation of HGF/SF in the morphogenetic program of rodent prostate development, the role of Met in normal human prostate epithelium, and underlying mechanisms of deregulated Met expression in localized and metastatic prostate cancer are discussed. On the basis of the commonly observed overexpression of Met in metastatic prostate cancer, HGF/SF-Met-targeted imaging and therapeutic agents can now be applied toward diagnosis and treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327888     DOI: 10.1016/S0065-230X(04)91002-0

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  35 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

2.  RasGRP3 contributes to formation and maintenance of the prostate cancer phenotype.

Authors:  Dazhi Yang; Noemi Kedei; Luowei Li; Juan Tao; Julia F Velasquez; Aleksandra M Michalowski; Balázs I Tóth; Rita Marincsák; Attila Varga; Tamás Bíró; Stuart H Yuspa; Peter M Blumberg
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

3.  C-Met/miR-130b axis as novel mechanism and biomarker for castration resistance state acquisition.

Authors:  A Cannistraci; G Federici; A Addario; A L Di Pace; L Grassi; G Muto; D Collura; M Signore; L De Salvo; S Sentinelli; G Simone; M Costantini; S Nanni; A Farsetti; V Coppola; R De Maria; D Bonci
Journal:  Oncogene       Date:  2017-02-13       Impact factor: 9.867

4.  The clinical value of serum hepatocyte growth factor levels in patients undergoing primary radiotherapy for glioma: effect on progression-free survival.

Authors:  Qing-le Liang; Zheng-ying Mo; Ping Wang; Xiao Li; Zhi-xiang Liu; Zhang-ming Zhou
Journal:  Med Oncol       Date:  2014-07-27       Impact factor: 3.064

Review 5.  Growth factor and signaling pathways and their relevance to prostate cancer therapeutics.

Authors:  Jocelyn L Wozney; Emmanuel S Antonarakis
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

Review 6.  Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.

Authors:  Leah M Cook; Gemma Shay; Arturo Araujo; Arturo Aruajo; Conor C Lynch
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

7.  Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.

Authors:  Jinlu Dai; Honglai Zhang; Andreas Karatsinides; Jill M Keller; Kenneth M Kozloff; Dana T Aftab; Frauke Schimmoller; Evan T Keller
Journal:  Clin Cancer Res       Date:  2013-10-04       Impact factor: 12.531

8.  Efficacy of c-Met inhibitor for advanced prostate cancer.

Authors:  William H Tu; Chunfang Zhu; Curtis Clark; James G Christensen; Zijie Sun
Journal:  BMC Cancer       Date:  2010-10-14       Impact factor: 4.430

Review 9.  Stroma-epithelium crosstalk in prostate cancer.

Authors:  Yi-Nong Niu; Shu-Jie Xia
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

10.  β4 Integrin signaling induces expansion of prostate tumor progenitors.

Authors:  Toshiaki Yoshioka; Javier Otero; Yu Chen; Young-Mi Kim; Jason A Koutcher; Jaya Satagopan; Victor Reuter; Brett Carver; Elisa de Stanchina; Katsuhiko Enomoto; Norman M Greenberg; Peter T Scardino; Howard I Scher; Charles L Sawyers; Filippo G Giancotti
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.